Skip to main content

Table 1 Ongoing clinical trials in adjuvant setting

From: Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research

Trial/Acronym Stage Marker Design Notes
RADIANT I-IIIA EGFR IHC pos 4 cycles of optional ACT followed by 2 years of TKI or placebo • Phase III, placebo controlled; Erlotinib 150 mg/die × 2 years
• Primary endpoint: DFS
ECOG 1505 IB (> 4 cm)-IIIA None Clinician choice ACT vs Clinician choice ACT + Bevacizumab • Phase III (2:1); Bevacizumab 15 mg/kg/3 wks
• Primary endpoint: OS
• Secondary endpoint: DFS, toxicities
SCAT I-IIIA BRCA CDDP DOC vs "gen assigned CT" • Phase III (3:1) CDDP DOC/DOC/CDDP GEM vs CDDP/DOC
• Primary endpoint: DFS
• Secondary endpoint: OS, toxicities
TASTE I-IIIA ERCC1/EGFR mutant CDDP/ERL • Phase II feasibility
SWOG 0720 I ERCC1/RRM1 Follow up or ACT according to risk profile • Phase II feasibility
MAGRIT IB-IIIA MAGE A3 + Vaccine vs placebo after optional ACT • Phase III (2:1) placebo controlled; separate analysis for ACT +/-
• Primary endpoint: DFS
• Secondary endpoint: OS
ITACA II-IIIA ERCC1/TS ACT assigned according to markers expression • Phase III
• Primary end-point: OS
TREAT IB-IIIA None CDDP PEM vs CDDP GEM • Randomized phase II
• Primary endpoint: feasibility
• Secondary endpoint: toxicity, delivery
  1. EGFR: epidermal growth factor receptor; IHC: immunohistochemistry; ACT: adjuvant chemotherapy; TKI: tyrosine kinase inhibitors; DFS: disease-free survival; OS: overall survival; CDDP: cisplatin; DOC: docetaxel; GEM: gemcitabine; ERCC: Excision Repair Cross-Complementation gene; RRM: ribonucleotide reductase M1 gene; MAGE: melanoma-associated antigen; TS: thymidylate synthetase; PEM: pemetrexed.